Literature DB >> 8391966

Pharmacokinetic properties of the trypanocidal drug melarsoprol.

C Burri1, T Baltz, C Giroud, F Doua, H A Welker, R Brun.   

Abstract

With a biological assay and atomic absorption spectrometry we determined the level of melarsoprol in the serum and cerebrospinal fluid of 19 patients treated with melarsoprol in Daloa, Ivory Coast. Most serum levels were between 2 and 4 micrograms/ml 24 h after administration, and were still > or = 0.1 microgram/ml after 120 h. Levels in the cerebrospinal fluid were between 0 and 0.1 microgram/ml. Elimination was biphasic, with a pronounced beta 1 phase. Mean terminal elimination half-life of melarsoprol was about 35 h, volume of distribution was about 100 l and total clearance was about 50 ml/min. The results of these first pharmacokinetic studies on melarsoprol were used to simulate possible alternative therapy schemes which might avoid some of the problems that arise with melarsoprol use.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8391966     DOI: 10.1159/000239130

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  12 in total

Review 1.  Tropical medicine.

Authors:  H W Murray; J Pépin; T B Nutman; S L Hoffman; A A Mahmoud
Journal:  BMJ       Date:  2000-02-19

Review 2.  Kinetoplastids: related protozoan pathogens, different diseases.

Authors:  Ken Stuart; Reto Brun; Simon Croft; Alan Fairlamb; Ricardo E Gürtler; Jim McKerrow; Steve Reed; Rick Tarleton
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

3.  New antitrypanosomal tetranotriterpenoids from Azadirachta indica.

Authors:  Mercy Githua; Ahmed Hassanali; Joseph Keriko; Grace Murilla; Mary Ndungu; Gathu Nyagah
Journal:  Afr J Tradit Complement Altern Med       Date:  2010-04-03

Review 4.  Arsenicals (melarsoprol), pentamidine and suramin in the treatment of human African trypanosomiasis.

Authors:  Andrew Jonathan Nok
Journal:  Parasitol Res       Date:  2003-01-31       Impact factor: 2.289

Review 5.  Human African trypanosomiasis: pharmacological re-engagement with a neglected disease.

Authors:  M P Barrett; D W Boykin; R Brun; R R Tidwell
Journal:  Br J Pharmacol       Date:  2007-07-09       Impact factor: 8.739

Review 6.  Pharmacokinetic and pharmacodynamic issues in the treatment of parasitic infections.

Authors:  G Edwards; S Krishna
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-17       Impact factor: 3.267

7.  Safety and efficacy of the 10-day melarsoprol schedule for the treatment of second stage Rhodesiense sleeping sickness.

Authors:  Irene Kuepfer; Caecilia Schmid; Mpairwe Allan; Andrew Edielu; Emma P Haary; Abbas Kakembo; Stafford Kibona; Johannes Blum; Christian Burri
Journal:  PLoS Negl Trop Dis       Date:  2012-08-28

8.  Trypanosomiasis relapse after melarsoprol therapy, Democratic Republic of Congo, 1982-2001.

Authors:  Jacques Pépin; Bokelo Mpia
Journal:  Emerg Infect Dis       Date:  2005-06       Impact factor: 6.883

Review 9.  Lack of Clinical Pharmacokinetic Studies to Optimize the Treatment of Neglected Tropical Diseases: A Systematic Review.

Authors:  Luka Verrest; Thomas P C Dorlo
Journal:  Clin Pharmacokinet       Date:  2017-06       Impact factor: 6.447

10.  Aquaporin 2 mutations in Trypanosoma brucei gambiense field isolates correlate with decreased susceptibility to pentamidine and melarsoprol.

Authors:  Fabrice E Graf; Philipp Ludin; Tanja Wenzler; Marcel Kaiser; Reto Brun; Patient Pati Pyana; Philippe Büscher; Harry P de Koning; David Horn; Pascal Mäser
Journal:  PLoS Negl Trop Dis       Date:  2013-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.